Explore InOncology.com to find out how Boehringer Ingelheim is taking cancer on. Our goal is to develop innovative, first-in-class treatments that can transform the lives of patients and help win the fight against cancer. To achieve this, we are searching for, developing and accelerating novel therapeutic approaches to address the current unmet needs in both lung and gastrointestinal cancers.
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
**Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
^Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.
© 2020 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: February 2020
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue